Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Catalent will provide development, manufacturing and commercialization services for lenzilumab, Humanigen’s anti-human GM-CSF monoclonal antibody.
read more
Tuesday, October 12, 2021
Humanigen announced it has entered into an arrangement with Clinigen to implement a Managed Access Program for lenzilumab (“LenzMAP™”).
read more
Monday, February 08, 2021
Avid Bioservices and Humanigen have entered into a manufacturing services agreement to expand production capacity for lenzilumab, Humanigen’s therapeutic candidate in development for COVID-19.
read more
Monday, November 23, 2020
Humanigen announced the company and the DoD have entered into a CRADA in collaboration with the BARDA in support of Operation Warp Speed to assist in the development of lenzilumab as a potential COVID-19 treatment.
read more
Monday, September 28, 2020
Humanigen announced a strategic collaboration with Thermo Fisher Scientific to expand the manufacturing capacity for lenzilumab, currently in a Phase 3 registration study in patients with COVID-19.
read more
Monday, September 18, 2017
PuraCap announced the FDA has completed a successful general inspection of its affiliated soft gelatin capsule manufacturing facility located in Wuhan, Hubei Province China.
read more
Thursday, February 20, 2020
Hummingbird Bioscience has signed an agreement with Mycenax Biotech for the production of material for the Phase 1 clinical trial of its HMBD-002 program.
read more
Huntingdon Life Sciences and Harlan Laboratories have announced that the combined companies will be called Envigo.
read more
Friday, September 18, 2015
On September 21, 2015, our group of companies, which presently comprises the trading companies, Huntingdon Life Sciences, Harlan Laboratories, GFA, NDA Analytics, LSR associates and various affiliates will be rebranded as Envigo (pronounced En-vee-go...
read more
Wednesday, February 25, 2015
Huntingdon Life Sciences (HLS) and Harlan Laboratories have announced that the two companies will be rebranded to reflect the new integrated management structure that has been put in place and the broader product and service offerings of the combined...
read more
Thursday, December 03, 2015
HUYA Bioscience International, a company accelerating drug discovery and development of biopharma innovation originating in China, recently opened its first corporate office in Korea.
read more
HUYA Bioscience International has announced the appointment of Akira Miyazato, MD, Ph.D. as VP, Head of Clinical Research and Development in Japan.
read more
HUYABIO has entered into a clinical collaboration agreement with Bristol-Myers Squibb to evaluate the combination of HUYABIO's HBI-8000.
read more
Thursday, August 29, 2024
Hyundai Bioscience Co., Ltd, currently pursuing Emergency Use Authorization (EUA) for its oral COVID-19 treatment, Xafty®, for mild-to-moderate cases, announced on August 27th that it has submitted an Investigational New Drug (IND) application for ...
read more
Thursday, January 02, 2025
GMP cell CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that the number of GMP-grade iPS cells manufactured has reached 100 lines.
read more